NCT02702414View on ClinicalTrials.gov

Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)

PHASE2CompletedINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

January 19, 2021

Study Completion Date

September 29, 2023

Conditions
Hepatocellular Carcinoma
Interventions
BIOLOGICAL

Pembrolizumab

Intravenous (IV) infusion

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02702414 - Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) | Biotech Hunter | Biotech Hunter